These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa]. Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC. Nefrologia; 2004 Jun; 24(1):54-9. PubMed ID: 15083958 [Abstract] [Full Text] [Related]
9. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F. Nefrologia; 2003 Jun; 23(2):114-24. PubMed ID: 12778875 [Abstract] [Full Text] [Related]
14. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Am J Nephrol; 2006 Jun; 26(2):149-56. PubMed ID: 16636531 [Abstract] [Full Text] [Related]
16. Medicare program; coverage of epoetin (EPO) used by competent home dialysis patients--HCFA. Final rule. Fed Regist; 1994 Jan 10; 59(6):1278-85. PubMed ID: 10133081 [Abstract] [Full Text] [Related]